Employing preclinical, ex vivo, in vivo, and in vitro model systems investigators determined that GLP-1 agonists exert anti-inflammatory and immune modulating effects through their effects on macrophages (reduced interleukin [IL] 1, IL-6, tumor necrosis factor [TNF], and C-X-C motif chemokine ligand [CXCL]), T and B lymphocytes (reduced cluster of differentiation [CD] 4 cells), monocytes (increased IL-10), mononuclear cells (decreased monocyte chemoattractant protein [MCP]1, cell death protein [PD],, CD4 and CD8 T cells) [51,52,53,54,55]
WeightWatchers has been around since 1963
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506)
Example: A note stating "injection administered in the right thigh" helps clarify the documentation
Any discrepancies in these evaluations between the two authors were then reviewed by both authors and a consensus achieved